Lung Disease News |
Breo Ellipta Now Approved as Asthma Treatment for Adult Patients in Canada
Lung Disease News GlaxoSmithKline (GSK) and VIBATIV® (telavancin) developer Theravance Biopharma, have just been granted Canadian approval for Breo Ellipta, a once-a-day maintenance treatment for asthma in patients who are at least 18 years old and have reversible … |
View full post on asthma – Google News